In conclusion, lacking exogenous TLR signaling, IL-6 augments short-term engraftment of B-CLL, while in the presence of TLR7 agonists, IL-6 operates as a leukemia suppressor by reducing its evolution. The gene discussed is IL6; the disease is leukemia.